Table 5.
Results of multiple regression analyses with the health-related quality of life (QoL) scores as measured with the Health Organization Quality of Life Instrument-Abridged Version (WHO-QoL) domain scores as dependent variables and being infected with the SARS-CoV-2 virus, treatments, vaccinations and clinical data as explanatory variables.
| Dependent Variables | Explanatory Variables | B | t | p | F Model | df | p | R2 |
|---|---|---|---|---|---|---|---|---|
| PC_WHO-QoL 4 domains | Model#1 | 167.94 | 4/120 | <0.001 | 0.848 | |||
| Acute infection | −0.644 | −8.50 | <0.001 | |||||
| Pure BDI | −0.354 | −6.95 | <0.001 | |||||
| Pure FF | −0.274 | −6.10 | <0.001 | |||||
| Enoxaparin | 0.262 | 4.08 | <0.001 | |||||
| WHO-QoL physical | Model#2 | 65.39 | 4/120 | <0.001 | 0.686 | |||
| Acute infection | −0.525 | −6.49 | <0.001 | |||||
| PBT | −0.238 | −3.16 | 0.002 | |||||
| Ceftriaxone | −0.165 | −2.68 | 0.008 | |||||
| Vaccination A | −0.103 | −2.00 | 0.048 | |||||
| WHO-QoL environmental | Model#3 | 89.82 | 2/122 | <0.001 | 0.596 | |||
| Acute infection | −1.054 | −10.35 | <0.001 | |||||
| Enoxaparin | 0.379 | 3.72 | <0.001 | |||||
PC_WHO-QoL 4 domains: principal component extracted from the 4 domains of the WHO-QoL-BREF (World Health Organization Quality of Life Instrument-Abridged Version) scale, BDI: Beck Depression Inventory; FF: Fibro-Fatigue scale; PBT: peak body temperature 3.5. Results of PLS Analysis.